CTPH-08 / Celltrion - LARVOL DELTA

A novel synergistic dual-payload FRα ADC (CTPH-08) that can potentially offer benefits for low IHC+ ovarian cancer patients by improving MTD and MED (AACR 2026) - "Although folate receptor-alpha (FRα) represents a clinically validated antigen as highlighted by the approval of Elahere, clinical benefit is yet to remain limited due to dose-limiting toxicities and suboptimal response durability. This presentation covers a comprehensive characterization of FRα AD2C including in vitro cytotoxicity for cancer cells with different levels of FRα expression, in vivo anti-tumor activities in FRα-positive CDX models, in vivo stability of FRα AD2C via pharmacokinetic assessment in rats, and preliminary safety evaluation in mice. We are currently advancing dual-payload FRα ADC(AD2C) toward PDX efficacy studies and GLP toxicology studies in order to proceed to Ph1 IND filing in due course."

ADC • Clinical • Oncology • Ovarian Cancer • Solid Tumor • FOLR1